Ubs Asset Management Americas Inc Beam Therapeutics Inc. Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 401,286 shares of BEAM stock, worth $10.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
401,286
Previous 419,569
4.36%
Holding current value
$10.3 Million
Previous $9.83 Million
0.01%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding BEAM
# of Institutions
235Shares Held
76.2MCall Options Held
438KPut Options Held
232K-
Farallon Capital Management LLC San Francisco, CA8.21MShares$211 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.84MShares$202 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$197 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.07MShares$182 Million1.53% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.83MShares$124 Million71.21% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.81B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...